Newel Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 20.01%
(FY 2023)
- Profit 9.33%
(FY 2023)
- Ebitda 84.81%
(FY 2023)
- Net Worth 27.48%
(FY 2023)
- Total Assets 17.03%
(FY 2023)
About Newel Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jinal Bharatkumar and Jaymin Parikh serve as directors at the Company.
- CIN/LLPIN
U24100GJ2015PTC083342
- Company No.
083342
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Newel Lifesciences Private Limited offer?
Newel Lifesciences Private Limited offers a wide range of products and services, including Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Anti Ulcer Drugs, Oxetacaine, Anti Inflammatory Drugs, Methylprednisolone Injection, Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Newel Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jinal Bharatkumar  | Director | 30-Dec-2018 | Current |
| Jaymin Parikh | Director | 27-May-2015 | Current |
Financial Performance of Newel Lifesciences.
Newel Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.01% increase. The company also saw a slight improvement in profitability, with a 9.33% increase in profit. The company's net worth Soared by an impressive increase of 27.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Newel Lifesciences?
In 2023, Newel Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Newel Lifesciences?
Unlock and access historical data on people associated with Newel Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Newel Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Newel Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
